Received Nov 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | YN2X2 | — |
Unapproved age; received kinrix when he should have received Tdap and Polio separately; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 8-year-old male patient who received DTPa-IPV (Kinrix) (batch number YN2X2, expiry date 16-OCT-2026) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Tdap Vaccine) for prophylaxis and Polio vaccine for prophylaxis. On 21-OCT-2025, the patient received Kinrix. The patient did not receive Tdap Vaccine and Polio vaccine. On 21-OCT-2025, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Unapproved age) and wrong vaccine administered (Verbatim: received kinrix when he should have received Tdap and Polio separately). The outcome of the inappropriate age at vaccine administration and wrong vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 21-OCT-2025 The patient was administered Kinrix when the intended plan was to give Tdap and polio vaccine separately. The reporter asked whether this administration was harmful.